{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab&page=24", "query": { "intervention": "trastuzumab", "page": 24 }, "page_size": 10 }, "pagination": { "page": 24, "page_size": 10, "total_count": 678, "total_pages": 68, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab&page=25&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=trastuzumab&page=23&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-20T00:25:23.933Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00266110", "title": "Vaccine Therapy, Trastuzumab, and Vinorelbine in Treating Patients With Locally Recurrent or Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "sargramostim", "type": "BIOLOGICAL" }, { "name": "therapeutic autologous dendritic cells", "type": "BIOLOGICAL" }, { "name": "trastuzumab", "type": "BIOLOGICAL" }, { "name": "vinorelbine ditartrate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "UNC Lineberger Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2005-12", "completion_date": "2017-10-27", "has_results": true, "last_update_posted_date": "2018-09-12", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 1, "location_summary": "Chapel Hill, North Carolina", "locations": [ { "city": "Chapel Hill", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00266110" }, { "nct_id": "NCT02947685", "title": "Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER-2 Positive Breast Cancer", "Estrogen Receptor Positive Breast Cancer" ], "interventions": [ { "name": "palbociclib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "pertuzumab", "type": "DRUG" }, { "name": "letrozole", "type": "DRUG" }, { "name": "Anastrozole", "type": "DRUG" }, { "name": "Exemestane", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alliance Foundation Trials, LLC.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2017-06-21", "completion_date": "2026-07-31", "has_results": true, "last_update_posted_date": "2026-02-12", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 35, "location_summary": "San Francisco, California • Washington D.C., District of Columbia • Clearwater, Florida + 30 more", "locations": [ { "city": "San Francisco", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Clearwater", "state": "Florida" }, { "city": "Hollywood", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02947685" }, { "nct_id": "NCT03742102", "title": "A Study of Novel Anti-cancer Agents in Patients With Metastatic Triple Negative Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Neoplasms" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Capivasertib", "type": "DRUG" }, { "name": "Oleclumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Trastuzumab deruxtecan", "type": "DRUG" }, { "name": "Datopotamab deruxtecan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "130 Years", "sex": "FEMALE", "summary": "18 Years to 130 Years · Female only" }, "enrollment_count": 243, "start_date": "2018-12-21", "completion_date": "2027-02-26", "has_results": true, "last_update_posted_date": "2026-08-04", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 8, "location_summary": "Tucson, Arizona • Columbia, Maryland • Boston, Massachusetts + 4 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Columbia", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Grand Rapids", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03742102" }, { "nct_id": "NCT00684983", "title": "Capecitabine and Lapatinib Ditosylate With or Without Cixutumumab in Treating Patients With Previously Treated HER2-Positive Stage IIIB-IV Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Positive Breast Carcinoma", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7" ], "interventions": [ { "name": "Capecitabine", "type": "DRUG" }, { "name": "Cixutumumab", "type": "BIOLOGICAL" }, { "name": "Lapatinib Ditosylate", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 64, "start_date": "2008-07-30", "completion_date": "2019-10-15", "has_results": true, "last_update_posted_date": "2020-03-24", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 390, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Berkeley, California + 274 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Castro Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00684983" }, { "nct_id": "NCT04499924", "title": "Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Gastric Adenocarcinoma", "Gastroesophageal Junction Adenocarcinoma", "Esophageal Adenocarcinoma" ], "interventions": [ { "name": "tucatinib", "type": "DRUG" }, { "name": "trastuzumab", "type": "DRUG" }, { "name": "ramucirumab", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "tucatinib placebo", "type": "OTHER" }, { "name": "trastuzumab placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Seagen Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2021-03-22", "completion_date": "2024-04-17", "has_results": true, "last_update_posted_date": "2025-01-22", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04499924" }, { "nct_id": "NCT00043394", "title": "CPG 7909 Plus Herceptin® In Patients With Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Carcinoma, Breast" ], "interventions": [ { "name": "0.04 mg/kg CpG 7909", "type": "DRUG" }, { "name": "Herceptin®", "type": "DRUG" }, { "name": "0.08 mg/kg CpG 7909", "type": "DRUG" }, { "name": "0.12 mg/kg CpG 7909", "type": "DRUG" }, { "name": "0.16 mg/kg CpG 7909", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 16, "start_date": "2002-09", "completion_date": "2003-10", "has_results": false, "last_update_posted_date": "2009-03-12", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 12, "location_summary": "Berkely, California • Orange, California • Palm Springs, California + 9 more", "locations": [ { "city": "Berkely", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00043394" }, { "nct_id": "NCT02023996", "title": "PET Imaging With 89Zr-DFO-Trastuzumab in Esophagogastric Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Esophagogastric Cancer" ], "interventions": [ { "name": "89Zr-DFO-trastuzumab", "type": "RADIATION" }, { "name": "PET imaging", "type": "DEVICE" } ], "intervention_types": [ "RADIATION", "DEVICE" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2013-12", "completion_date": "2023-06-27", "has_results": true, "last_update_posted_date": "2024-12-10", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02023996" }, { "nct_id": "NCT00146042", "title": "UMCC 9901: Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER-2 Positive Metastatic Breast Cancer" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Erythromycin Breath Test (ERMBT)", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 22, "start_date": "1999-03", "completion_date": "2005-03", "has_results": false, "last_update_posted_date": "2012-10-05", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00146042" }, { "nct_id": "NCT02091960", "title": "A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HER2 Amplified", "Advanced Breast Cancer", "Human Epidermal Growth Factor Receptor 2 (HER2)" ], "interventions": [ { "name": "Enzalutamide", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Astellas Pharma Global Development, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 103, "start_date": "2014-09-05", "completion_date": "2024-01-30", "has_results": true, "last_update_posted_date": "2025-04-04", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 16, "location_summary": "Anaheim, California • Los Angeles, California • San Francisco, California + 12 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Fort Myers", "state": "Florida" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02091960" }, { "nct_id": "NCT01730118", "title": "Ad/HER2/Neu Dendritic Cell Cancer Vaccine Testing", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Neoplasms", "Breast Cancer", "Adenocarcinomas", "Metastatic Solid Tumors Characterized by HER2/Neu Expression" ], "interventions": [ { "name": "Adenoviral Transduced Autologous Human Epidermal Growth Factor Receptor (AdHER)2/neu Dendritic Cell (DC) Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2013-03-04", "completion_date": "2019-12-03", "has_results": true, "last_update_posted_date": "2022-09-10", "last_synced_at": "2026-10-20T00:25:23.933Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01730118" } ] }